You are currently viewing No NHS Coverage for Janssen’s Spravato: NICE Denies Re-Appraisal of Esketamine for TRD

No NHS Coverage for Janssen’s Spravato: NICE Denies Re-Appraisal of Esketamine for TRD

Earlier this month, the National Institute for Health and Care Excellence (NICE), which stipulates which medical interventions are covered by England and Wales’ National Health Service (NHS), issued a statement that effectively brings Janssen’s ambitions to have its esketamine nasal spray (Spravato) product for treatment-resistant depression (TRD) reimbursed by the NHS in the UK’s most populous countries to a close.

After a half-decade of back-and-forth, the agency has again stood by its recommendation that Spravato not be covered by the state-backed health system. That original recommendation, delivered in 2020, revealed that the public body was not convinced by the product’s clinical data or cost-effectiveness.

The remit of this latest review, then, was “to consider whether any evidence presented would change the current recommendation”, NICE explained. It concluded that it would not.


  • A Half-Decade Battle Bears No Fruit for Janssen
  • Janssen Hoped Head-to-Head Quietiapine Study Might Quiet NICE’s Concerns
  • Implications for Psychedelic Therapies

To continue reading, please log in or join Pα+…

Join Pα+ Today

Independent data-driven reporting, analysis and commentary on the psychedelics space: from business and drug development through to policy reform and culture.

Already a member? Log In

   Regular Bulletins covering key topics and trends in the psychedelics space
   Regular articles and deep dives across psychedelic research, policy and business
   Interviews with insiders
   Monthly interactive database and commentary on psychedelic patents
   Quick-take analysis of major developments
   A Library of primers and explainers
   Access to our full back catalogue

Learn more about Pα+